Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
NCT00002290 · View on ClinicalTrials.gov ↗
Study Summary
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, severity, and time of development of opportunistic infections and other manifestations of advanced symptomatic HIV infection. The effects of the combination and single AZT therapy on immune function and viral replication will also be evaluated. Study participants will be monitored for evidence of toxicity or intolerance to concurrent AZT / ACV administration and AZT therapy alone.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Acyclovir
Study Locations (14)
Texas
- Univ TX Galveston Med Branch — Galveston
- Baylor College of Medicine — Houston
Virginia
- Univ of Virginia Health Sciences Ctr — Charlottesville
- Richmond AIDS Consortium — Richmond
Alabama
- Birmingham Veterans Administration Med Ctr / Univ of Alabama — Birmingham
Arizona
- Univ of Arizona / Health Science Ctr — Tucson
California
- ViRx Inc — San Francisco
District of Columbia
- Georgetown Univ Med Ctr / Main Hosp 4 — Washington D.C.
Florida
- Veterans Administration Med Ctr — Bay Pines
Illinois
- Rush Presbyterian - Saint Luke's Med Ctr — Chicago
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002290
The ClinicalTrials.gov registry entry for NCT00002290 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 18 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions — of which Zidovudine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00002290 reports 14 study locations spanning 12 distinct geographic areas — top geographies include Texas, Virginia, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00002290 about?
NCT00002290 is a clinical study titled "The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection". This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, ...
What is the current status of trial NCT00002290?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002290 study?
This clinical trial studies the following conditions: HIV Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00002290?
The interventions under investigation include: Zidovudine (DRUG), Acyclovir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00002290?
This trial is sponsored by Glaxo Wellcome, which has 18 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00002290 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.